The "One-to-Many" Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma.

MLA

Messori, Andrea, et al. “The ‘One-to-Many’ Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma.” Cureus, vol. 14, no. 8, Aug. 2022, p. e28369. EBSCOhost, https://doi.org/10.7759/cureus.28369.

APA

Messori, A., Rivano, M., Cancanelli, L., Damuzzo, V., Ossato, A., Chiumente, M., & Mengato, D. (2022). The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma. Cureus, 14(8), e28369. https://doi.org/10.7759/cureus.28369

Chicago

Messori, Andrea, Melania Rivano, Luca Cancanelli, Vera Damuzzo, Andrea Ossato, Marco Chiumente, and Daniele Mengato. 2022. “The ‘One-to-Many’ Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma.” Cureus 14 (8): e28369. doi:10.7759/cureus.28369.